Literature DB >> 28961792

Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse.

Asuka Nakarai1, Sakiko Hiraoka1, Sakuma Takahashi2, Tomoki Inaba2, Reiji Higashi3, Motowo Mizuno4, Shiho Takashima1, Toshihiro Inokuchi1, Yuusaku Sugihara1, Masahiro Takahara1, Keita Harada5, Jun Kato6, Hiroyuki Okada1.   

Abstract

BACKGROUND: Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown.
METHODS: UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined.
RESULTS: A total of 113 patients were enrolled, and 48 [42%] relapsed. Fcal ≥ 75 μg/g and FIT ≥ 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively, according to the receiver operating characteristic curves. Both Fcal-positive and FIT-positive statuses were independent predictive factors of clinical relapse (hazard ratio [HR] 2.29; 95% confidence interval [CI], 1.23-4.49; p = 0.0086, and HR 2.91; 95% CI, 1.49-5.50; p = 0.0022, respectively). Categorisation of patients into three groups according to the faecal marker status [FIT-positive, FIT-negative and Fcal-positive, and both negative] can efficiently stratify the risk of relapse with graded increases in risk [FIT-negative and Fcal-positive: HR 2.05; 95% CI, 1.02-4.43; p = 0.0045, and FIT-positive: HR 5.43; 95% CI, 2.57-11.76; p < 0.0001, compared with both negative].
CONCLUSIONS: Fcal vs FIT showed distinct properties regarding the prediction of relapse in UC. A risk assessment using both faecal markers could increase the predictability for relapse.
Copyright © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  Ulcerative colitis; faecal calprotectin; quantitative faecal immunochemical test; relapse

Mesh:

Substances:

Year:  2018        PMID: 28961792     DOI: 10.1093/ecco-jcc/jjx118

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  11 in total

1.  Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Bing-Jie Xiang; Min Jiang; Ming-Jun Sun; Cong Dai
Journal:  Visc Med       Date:  2021-01-21

2.  Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis.

Authors:  Hsu-Heng Yen; Mei-Wen Chen; Yu-Yao Chang; Hsuan-Yuan Huang; Tsui-Chun Hsu; Yang-Yuan Chen
Journal:  PeerJ       Date:  2020-07-14       Impact factor: 2.984

3.  Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy.

Authors:  Natsuki Ishida; Yusuke Asai; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-06-08

Review 4.  The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases.

Authors:  Bianca J Galgut; Daniel A Lemberg; Andrew S Day; Steven T Leach
Journal:  Front Pediatr       Date:  2018-01-19       Impact factor: 3.418

5.  Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission.

Authors:  Natsuki Ishida; Kiichi Sugiura; Takahiro Miyazu; Satoshi Tamura; Satoshi Suzuki; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Clin Transl Gastroenterol       Date:  2020-12       Impact factor: 4.396

6.  Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse.

Authors:  Natsuki Ishida; Shunya Onoue; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Int J Colorectal Dis       Date:  2021-08-18       Impact factor: 2.571

7.  Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis.

Authors:  Natsuki Ishida; Shinya Tani; Yusuke Asai; Takahiro Miyazu; Satoshi Tamura; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Sci Rep       Date:  2022-08-09       Impact factor: 4.996

8.  Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study.

Authors:  Natsuki Ishida; Masanao Kaneko; Yusuke Asai; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  BMC Gastroenterol       Date:  2022-09-15       Impact factor: 2.847

9.  Alternative diagnoses and demographics associated with a raised quantitative faecal immunochemical test in symptomatic patients.

Authors:  Mark S Johnstone; Gillian Miller; Grace Pang; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley
Journal:  Ann Clin Biochem       Date:  2022-03-03       Impact factor: 2.587

10.  Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome.

Authors:  Natsuki Ishida; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.